Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Randomized, Placebo-controlled, Double-blind, Dose-escalation Study of the Safety and Immunogenicity of NasoShield

NCT03352466 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT03352466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03352466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Randomized, Placebo-controlled, Double-blind, Dose-escalation Study of the Safety and Immunogenicity of NasoShield
Lead sponsor
Altimmune, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 18, 2018
Completion date
May 13, 2019
Enrollment
145 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers